IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Analysts

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fourteen analysts that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $54.27.

IDYA has been the subject of a number of recent analyst reports. Stephens restated an "overweight" rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a report on Friday, February 14th. JPMorgan Chase & Co. lifted their target price on IDEAYA Biosciences from $63.00 to $66.00 and gave the stock an "overweight" rating in a research report on Thursday, May 22nd.

IDEAYA Biosciences Trading Up 3.1%

Shares of IDYA stock traded up $0.58 during trading hours on Thursday, reaching $19.40. 436,585 shares of the stock were exchanged, compared to its average volume of 1,166,911. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -5.90 and a beta of 0.26. IDEAYA Biosciences has a 12-month low of $13.45 and a 12-month high of $44.42. The company's 50-day moving average price is $17.67 and its 200-day moving average price is $21.71.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter last year, the firm posted ($0.53) earnings per share. On average, sell-side analysts expect that IDEAYA Biosciences will post -3.07 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Barclays PLC boosted its holdings in IDEAYA Biosciences by 188.8% in the third quarter. Barclays PLC now owns 181,170 shares of the company's stock worth $5,739,000 after acquiring an additional 118,438 shares in the last quarter. SG Americas Securities LLC increased its stake in IDEAYA Biosciences by 444.2% during the 4th quarter. SG Americas Securities LLC now owns 18,486 shares of the company's stock valued at $475,000 after purchasing an additional 15,089 shares in the last quarter. KBC Group NV raised its holdings in shares of IDEAYA Biosciences by 84.6% in the fourth quarter. KBC Group NV now owns 4,197 shares of the company's stock worth $108,000 after buying an additional 1,923 shares during the last quarter. R Squared Ltd acquired a new stake in shares of IDEAYA Biosciences during the fourth quarter worth $35,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of IDEAYA Biosciences by 12.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,327 shares of the company's stock worth $471,000 after buying an additional 2,078 shares during the period. Hedge funds and other institutional investors own 98.29% of the company's stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.